[go: up one dir, main page]

DK1997811T3 - Indazol-, benzoxazol- og pyrozolopyridinderivater som P38-kinasehæmmere - Google Patents

Indazol-, benzoxazol- og pyrozolopyridinderivater som P38-kinasehæmmere Download PDF

Info

Publication number
DK1997811T3
DK1997811T3 DK08164861.0T DK08164861T DK1997811T3 DK 1997811 T3 DK1997811 T3 DK 1997811T3 DK 08164861 T DK08164861 T DK 08164861T DK 1997811 T3 DK1997811 T3 DK 1997811T3
Authority
DK
Denmark
Prior art keywords
cycloalkyl
heterocycloalkyl
alkyl
mmol
heteroalkyl
Prior art date
Application number
DK08164861.0T
Other languages
English (en)
Inventor
Mark Munson
David A Mareska
Robert Groneberg
James Rizzi
Ganghyeok Kim
Guy Vigers
Chang Rao
Darren Harvey
Martha Rodriguez
Devan Balachari
Youngboo Kim
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Priority claimed from EP04714621A external-priority patent/EP1606283B1/en
Application granted granted Critical
Publication of DK1997811T3 publication Critical patent/DK1997811T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Claims (13)

1
1. Forbindelse, der indbefatter opløste enantiomerer, diastereomerer, solvater og farmaceutisk acceptable salte deraf, hvilken forbindelse har formlen XVII: 5 r T OJL Rx-Q-Ry <o(oJ XVII hvor Y er O, NR2; 10 WerCR3; R3 er H, NH2, F, Cl, methyl eller substitueret methyl; R2 er H, OH, en aminbeskyttelsesgruppe, Zn-NRaRb, Zn-NRa(C=0)Rb, zn-S02Ra, Zn-SORa, Zn-SRa, Zn-ORa, Zn-(C=0)Ra, Zn-(C=0)0Ra, Zn-0-(C=0)Ra, alkyl, allyl, alkenyl, alkynyl, heteroalkyl, heteroallyl, heteroalkenyl, 15 heteroalkynyl, alkoxy, heteroalkoxy, Zn-cycloalkyl, hvor cycloalkyl er mættet eller delvist umættet, Zn-heterocycloalkyl, hvor heterocycloalkyl er mættet eller delvist umættet, eller Zn-Ar1, hvor alkyl, allyl, alkenyl, alkynyl, heteroalkyl, heteroallyl, heteroalkenyl, heteroalkynyl, alkoxy, heteroalkoxy, Zn-cycloalkyl, Zn-heterocycloalkyl og Zn-Ar1 kan være substitueret eller ikke-2 0 substitueret; Ar1 er aryl eller heteroaryl, der begge kan være substitueret eller ikke-substitueret; Ra og Rb uafhængigt er H, OH, en aminbeskyttelsesgruppe, en alkoholbeskyttelsesgruppe, en syrebeskyttelsesgruppe, en 2 5 svovlbeskyttelsesgruppe, alkyl, allyl, alkenyl, alkynyl, heteroalkyl, heteroallyl, heteroalkenyl, heteroalkynyl, alkoxy, heteroalkoxy, Zn-cycloalkyl, hvor cycloalkyl er mættet eller delvist umættet, Zn-heterocycloalkyl, hvor heterocycloalkyl er mættet eller delvist umættet, eller Zn-Ar1, hvor alkyl, allyl, alkenyl, alkynyl, heteroalkyl, heteroallyl, heteroalkenyl, heteroalkynyl, alkoxy, heteroalkoxy, Zn-cycloalkyl, Zn-heterocycloalkyl og Zn-Ar1 kan være substitueret eller ikke-substitueret, eller Ra og Rb sammen med de atomer, hvortil de begge er bundet, danner en mættet eller delvist umættet heterocyklusring med 1 eller flere heteroatomer i ringen, hvor heterocyklussen kan være substitueret eller ikke-substitueret, og hvor heterocyklussen kan være kondenseret til en aromatisk ring; Z er alkylen, der har fra 1 til 4 carboner, eller alkenylen eller alkynylen, der hver har fra 2 til 4 carboner, hvor alkylen, alkenylen eller alkynylen kan være substitueret eller ikke-substitueret; n er 0 eller 1; Uer CRCeller N; V er CRC eller N; Rc er H, F, Cl, methyl eller substitueret methyl; X er O, S, SO, S02, NR5, C=0, CH2, CH2Zn-OH eller C=NORd; R5 er H, methyl eller substitueret methyl; Rd er H, P03H2, S03H2, alkyl, allyl, alkenyl, alkynyl, heteroalkyl, heteroallyl, heteroalkenyl, heteroalkynyl, alkoxy, heteroalkoxy, Zn-cycloalkyl, hvor cycloalkyl er mættet eller delvist umættet, Zn-heterocycloalkyl, hvor heterocycloalkyl er mættet eller delvist umættet, eller Zn-Ar1, hvor alkyl, allyl, alkenyl, alkynyl, heteroalkyl, heteroallyl, heteroalkenyl, heteroalkynyl, alkoxy, heteroalkoxy, Zn-cycloalkyl, Zn-heterocycloalkyl og Zn-Ar1 kan være substitueret eller ikke-substitueret; G, K, J, og T uafhængigt er N eller CRZ, forudsat, når en hvilken som helst af G, K, J og T er N, at det totale antal af G, K, J, eller T, der er N, ikke overstiger 2; Rz er H, F, Cl, Br, CF3, OR6, SR6, lavere alkyl (CrC4), CN, eller NR6R7; R6 og R7 uafhængigt er H, CF3, lavere alkyl (CrC4) eller lavere heteroalkyl (CrC4); Q er -NR8CONH-, -NHCO-, -NR8S02NH-, -NHS02-, -CONR11-; R8 er H eller (CrC4) alkyl; R11 er H eller (CrC4) alkyl; Rx er -(CR9R10)m-, -O(CR9R10)m-, NH(CR9R10)m- eller -S(CR9R10)m- forudsat at Q er -CONR11-, når Rx er -O(CR9R10)m_, -NH(CR9R10)m eller -S(CR9R10)m-; R9 og R10 uafhængigt er H eller lavere alkyl, eller R9 og R10 sammen med de atomer, hvortil de begge er bundet, danner en cycloalkylring, der kan være mættet eller delvist umættet; m er 1-3; Ry er H, P03H, en aminbeskyttelsesgruppe, en oxygenbeskyttelsesgruppe, alkyl, allyl, alkenyl, alkynyl, heteroalkyl, heteroallyl, heteroalkenyl, heteroalkynyl, alkoxy, heteroalkoxy, Zn-cycloalkyl, hvor cycloalkyl er mættet eller delvist umættet, Zn-heterocycloalkyl, hvor heterocycloalkyl er mættet eller delvist umættet, eller Zn-Ar2, hvor alkyl, allyl, alkenyl, alkynyl, heteroalkyl, heteroallyl, heteroalkenyl, heteroalkynyl, alkoxy, heteroalkoxy, Zn-cycloalkyl, Zn-Ar2 og Zn-heterocycloalkyl kan være substitueret eller ikke-substitueret; Ar2 er aryl eller heteroaryl, der begge kan være substitueret eller ikke-substitueret, hvor substitutionen kan være 1-3 substituenter uafhængigt udvalgt fra F, Cl, Br, CF3, CN, alkyl, allyl, alkenyl, alkynyl, heteroalkyl, heteroallyl, heteroalkenyl, heteroalkynyl, -OR12, -SR12, -S02R12, -S02NR13R12, NR13S02R12, Zn-cycloalkyl, hvor cycloalkyl er mættet eller delvist umættet, Zn-heterocycloalkyl, hvor heterocycloalkyl er mættet eller delvist umættet, eller Zn-Ar1, hvor alkyl, allyl, alkenyl, alkynyl, heteroalkyl, heteroallyl, heteroalkenyl, heteroalkynyl, alkoxy, heteroalkoxy, Zn-cycloalkyl, Zn-heterocycloalkyl og Zn-Ar1 kan være substitueret eller ikke-substitueret; R12 og R13 uafhængigt er H, alkyl, allyl, alkenyl, alkynyl, heteroalkyl, heteroallyl, heteroalkenyl, heteroalkynyl, Zn-cycloalkyl, hvor cycloalkyl er mættet eller delvist umættet, Zn-heterocycloalkyl, hvor heterocycloalkyl er mættet eller delvist umættet, eller Zn-Ar1, hvor alkyl, allyl, alkenyl, alkynyl, heteroalkyl, heteroallyl, heteroalkenyl, heteroalkynyl, alkoxy, heteroalkoxy, Zn-cycloalkyl, Zn-heterocycloalkyl og Zn-Ar1 kan være substitueret eller ikke-substitueret; Hvor, når Ar2 er substitueret med -S02NR13R12, R12 og R13 kan danne en cycloalkylring eller heterocycloalkylring, der kan være substitueret eller ikke-substitueret, hvor substitutionen kan være substituenter udvalgt fra alkyl, allyl, alkenyl, alkynyl, heteroalkyl, heteroallyl, heteroalkenyl, heteroalkynyl, alkoxy, heteroalkoxy, Zn-cycloalkyl, hvor cycloalkyl er mættet eller delvist umættet, -COR12, -S02R12, Zn-heterocycloalkyl, hvor heterocycloalkyl er mættet eller delvist umættet, eller Zn-Ar1, hvor alkyl, allyl, alkenyl, alkynyl, heteroalkyl, heteroallyl, heteroalkenyl, heteroalkynyl, alkoxy, heteroalkoxy, Zn-cycloalkyl, Zn-heterocycloalkyl og Zn-Ar1 kan være substitueret eller ikke-substitueret; hvor, når Q er -CONR11, Ry i kombination med R11 endvidere er en cycloalkylring eller heterocycloalkylring, der kan være substitueret eller ikke-substitueret med grupper udvalgt fra alkyl, allyl, alkenyl, alkynyl, heteroalkyl, heteroallyl, heteroalkenyl, heteroalkynyl, alkoxy, heteroalkoxy, Zn-cycloalkyl, hvor cycloalkyl er mættet eller delvist umættet, Zn-heterocycloalkyl, hvor heterocycloalkyl er mættet eller delvist umættet, Zn-Ar1, -COR14, eller -S02R14, hvor alkyl, allyl, alkenyl, alkynyl, heteroalkyl, heteroallyl, heteroalkenyl, heteroalkynyl, alkoxy, heteroalkoxy, Zn-cycloalkyl, Zn-heterocycloalkyl, Zn-Ar1, -COR14, og -S02R14 kan være substitueret eller ikke-substitueret; og R14 er alkyl, allyl, alkenyl, alkynyl, heteroalkyl, heteroallyl, heteroalkenyl, heteroalkynyl, Zn-cycloalkyl, hvor cycloalkyl er mættet eller delvist umættet, Zn-heterocycloalkyl, hvor heterocycloalkyl er mættet eller delvist umættet, eller Zn-Ar1, hvor alkyl, allyl, alkenyl, alkynyl, heteroalkyl, heteroallyl, heteroalkenyl, heteroalkynyl, alkoxy, heteroalkoxy, Zn-cycloalkyl, Zn-heterocycloalkyl og Zn-Ar1 kan være substitueret eller ikke-substitueret, og hvor hver gruppes substituent(er) er udvalgt blandt: halo, alkyl, allyl, alkenyl, alkynyl, heteroalkyl, heteroallyl, heteroalkenyl, heteroalkynyl, alkoxy, heteroalkoxy, Zn-cycloalkyl, Zn-heterocycloalkyl, Zn-OR, Zn-N02, Zn-CN, Zn-C02R, Zn-(C=0)R, Zn-0(0=0)R, Zn-0-alkyl, Zn-OAr, Zn-SH, Zn-SR, Zn-SOR, Zn-S02R, Zn-S-Ar, Zn-SOAr, Zn-S02Ar, aryl, heteroaryl, Zn-Ar, Zn-(C=0)NR’R”, Zn-NR’R”, Zn-NR(C=0)R, Zn-S02NR’R”, P03H2, S03H2, aminbeskyttelsesgrupper, alkoholbeskyttelsesgrupper, svovlbeskyttelsesgrupper eller syrebeskyttelsesgrupper, hvor: Z er alkylen der har fra 1 til 4 carboner, eller alkenylen eller alkynylen, der hver har fra 2 til 4 carboner, n er nul eller 1, R, R’ og R” er alkyl, allyl, alkenyl, alkynyl, heteroalkyl, heteroallyl, heteroalkenyl, heteroalkynyl, alkoxy, heteroalkoxy, Zn-cycloalkyl eller Zn-heterocycloalkyl, og Ar er aryl eller heteroaryl.
2. Forbindelse ifølge krav 1, hvor W er CH og Y er NR2.
3. Forbindelse ifølge krav 1, hvor G, J, K og T er CRZ.
4. Forbindelse ifølge krav 1, hvor X er NH, S eller O.
5. Forbindelse ifølge krav 1, hvor Rx er CH2 og Q er -NHCO-. yv"'\ y— -t | S ' I ^ 0
6. Forbindelse ifølge krav 5, hvor Ry er isopropyl eller ^—* .
7. Forbindelse ifølge krav 1, hvor Rx er CH2 og Q er -NR8CONH-,
8. Forbindelse ifølge krav 7, hvor Ry er
9. Forbindelse ifølge et hvilket som helst af kravene 1 til 8, hvilken forbindelse er udvalgt fra gruppen bestående af: 1 -(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3[2-(1 -methyl-1 H-indazol-5-yloxy)-pyridin-3-ylmethyl]-urea, 1-[5-cyclopropyl-2-(4-trifluormethylphenyl)-2H-pyrazol-3yl]-3-(5-fluor-2-(1 -methyl-1 H-indazol-5-ylamino)-benzyl]-urea, 1 -(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[2-(1 -cyclobutylmethyl-1 H-indazol-5-ylamino)-5-fluorbenzyl]-urea, 1 -(5-tert-butyl-2-p-chlorphenyl-2H-pyrazol-3-yl)-3[2-(1 -methyl-1 H-indazo-5-ylsulfanyl)-5-fluorbenzyl]-urea, 1 -(5-tert-butyl-2-methy1 -2H-pyrazol-3-yl)-3-{2-[1 -(3-isopropylamino-propyl)-1H-indazol-5-ylamino]-benzyl}-urea, 1 -(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[5-fluor-2-(1 -methyl-1 H-indazol-5-yloxy)-benzyl]urea, 1 [5-tert-butyl-2-(4-chlorphenyl)-2H-pyrazol-3-yl]-3-[5-fluor-2-(1 -methyl-1 H-indazol-5-yloxy)-benzyl]urea, 3-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-1 -[5-fluor-2-(1 -methyl-1 H-indazol-5-yloxy)-benzyl]-1-methylurea, 1 -(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[5-fluor-2-(1 -methyl-1 H-indazol-5-yloxy)-benzyl]-1-methylurea, 1 -(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[5-fluor-2-(1 -methyl-1 H-pyrazol[3,4-c]pyridin-5-yloxy)-benzyl]-urea, 2-(5-{2-[3-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl}-ureidomethyl]-4- fluorphenoxy)-indazol-1-yl)-N,N-dimethylacetamid, 1 -(5-tert-butyl-isoxazol-3-yl)-3[5-fluor-2-(1 -isobutyl-1 H-indazol-5-yloxy)-benzyl]-urea, 1 -(3-tert-butyl-isoxazol-5-yl)-3-{5-fluor-2[1 -(2-piperazin-1 -yl-ethyl)-1 H-indazol-5-yloxy]-benzyl}urea, 1 -(3-tert-butyl-isoxazol-5-yl)-3-{2[1 -(2-dimethylaminoethyl)-1 H-indazol-5-yloxyl-5-fluor-benzyl)-urea, 1 -(5-tert-butyl-2-methyl-2H-pyrazol-3-yl)-3-{5-fluor-2-[1 -(2-hydroxy-2-methylpropyl)-1 H-indazol-5-yloxy]-benzyl}-urea og et farmaceutisk acceptabelt salt deraf.
10. Sammensætning omfattende en forbindelse ifølge krav 1 og et farmaceutisk acceptabelt bærestof.
11. Forbindelse ifølge et hvilket som helst af kravene 1 til 9 til anvendelse i terapi.
12. Forbindelse ifølge et hvilket som helst af kravene 1 til 9 til anvendelse ved behandling eller forebyggelse af en p-38-medieret tilstand.
13. Forbindelse ifølge krav 12, hvor den p-38-medierede tilstand er en inflammatorisk sygdom, autoimmun sygdom, destruktiv knogleforstyrrelse, proliferativ knogleforstyrrelse, infektionssygdom, virussygdom eller neurodegenerativ sygdom.
DK08164861.0T 2003-03-03 2004-02-25 Indazol-, benzoxazol- og pyrozolopyridinderivater som P38-kinasehæmmere DK1997811T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/378,164 US7135575B2 (en) 2003-03-03 2003-03-03 P38 inhibitors and methods of use thereof
US10/688,849 US20040180896A1 (en) 2003-03-03 2003-10-15 P38 inhibitors and methods of use thereof
EP04714621A EP1606283B1 (en) 2003-03-03 2004-02-25 P38 inhibitors and methods of use thereof

Publications (1)

Publication Number Publication Date
DK1997811T3 true DK1997811T3 (da) 2015-07-06

Family

ID=32926418

Family Applications (5)

Application Number Title Priority Date Filing Date
DK08164861.0T DK1997811T3 (da) 2003-03-03 2004-02-25 Indazol-, benzoxazol- og pyrozolopyridinderivater som P38-kinasehæmmere
DK08164856.0T DK1997809T3 (da) 2003-03-03 2004-02-25 P38-inhibitorer og fremgangsmåder til anvendelse deraf
DK08166014.4T DK2039685T3 (da) 2003-03-03 2004-02-25 Heterobicycliske forbindelser som P38-inhibitorer
DK04714621T DK1606283T3 (da) 2003-03-03 2004-02-25 P38-inhibitorer og fremgangsmåder til anvendelse deraf
DK08164860.2T DK1997810T3 (da) 2003-03-03 2004-02-25 Indazoler, benzotriazoler og N-analoger deraf som p38-kinaseinhibitorer

Family Applications After (4)

Application Number Title Priority Date Filing Date
DK08164856.0T DK1997809T3 (da) 2003-03-03 2004-02-25 P38-inhibitorer og fremgangsmåder til anvendelse deraf
DK08166014.4T DK2039685T3 (da) 2003-03-03 2004-02-25 Heterobicycliske forbindelser som P38-inhibitorer
DK04714621T DK1606283T3 (da) 2003-03-03 2004-02-25 P38-inhibitorer og fremgangsmåder til anvendelse deraf
DK08164860.2T DK1997810T3 (da) 2003-03-03 2004-02-25 Indazoler, benzotriazoler og N-analoger deraf som p38-kinaseinhibitorer

Country Status (29)

Country Link
US (5) US7135575B2 (da)
EP (4) EP2039685B1 (da)
JP (2) JP5424657B2 (da)
KR (3) KR20110091532A (da)
CN (2) CN100579976C (da)
AR (2) AR043451A1 (da)
AT (1) ATE410421T1 (da)
AU (1) AU2009225343B2 (da)
BR (2) BRPI0419305B8 (da)
CL (2) CL2004000416A1 (da)
CO (1) CO5670351A2 (da)
CY (4) CY1108661T1 (da)
DE (1) DE602004016970D1 (da)
DK (5) DK1997811T3 (da)
DO (1) DOP2009000155A (da)
EG (1) EG27049A (da)
ES (4) ES2484866T3 (da)
HK (2) HK1084673A1 (da)
IL (3) IL170527A (da)
IS (1) IS2959B (da)
NO (1) NO20085373L (da)
NZ (3) NZ582796A (da)
PA (1) PA8596901A1 (da)
PL (1) PL219742B1 (da)
PT (4) PT1997809E (da)
SI (5) SI1997809T1 (da)
TW (2) TWI346663B (da)
UA (2) UA86196C2 (da)
ZA (1) ZA200507874B (da)

Families Citing this family (364)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7893101B2 (en) * 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
JP4617299B2 (ja) * 2003-03-03 2011-01-19 アレイ バイオファーマ、インコーポレイテッド ｐ３８阻害剤及びその使用法
US7429378B2 (en) * 2003-05-13 2008-09-30 Depuy Spine, Inc. Transdiscal administration of high affinity anti-MMP inhibitors
US7553827B2 (en) * 2003-08-13 2009-06-30 Depuy Spine, Inc. Transdiscal administration of cycline compounds
US8273347B2 (en) * 2003-05-13 2012-09-25 Depuy Spine, Inc. Autologous treatment of degenerated disc with cells
US7344716B2 (en) * 2003-05-13 2008-03-18 Depuy Spine, Inc. Transdiscal administration of specific inhibitors of pro-inflammatory cytokines
AU2004272104B2 (en) * 2003-09-10 2011-09-08 Icagen, Inc Fused ring heterocycles as potassium channel modulators
AU2004282189B2 (en) 2003-10-17 2011-11-17 Incyte Holdings Corporation Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases
US8895540B2 (en) * 2003-11-26 2014-11-25 DePuy Synthes Products, LLC Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor
EP1706385B1 (en) 2003-12-23 2010-10-06 Astex Therapeutics Limited Pyrazole derivatives as protein kinase modulators
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
CN1922150A (zh) * 2004-02-27 2007-02-28 霍夫曼-拉罗奇有限公司 吲唑衍生物以及含有它们的药物组合物
EP1720878A1 (en) * 2004-02-27 2006-11-15 F.Hoffmann-La Roche Ag Heteroaryl-fused pyrazolo derivatives
CA2557575A1 (en) * 2004-02-27 2005-09-15 F. Hoffmann-La Roche Ag Fused derivatives of pyrazole
US7456209B2 (en) 2004-07-15 2008-11-25 Tetralogic Pharmaceuticals Corporation IAP binding compounds
DE602005010714D1 (de) * 2004-08-12 2008-12-11 Pfizer Der p38-map-kinase
EP1647549A1 (en) * 2004-10-14 2006-04-19 Laboratoire Theramex Indazoles, benzisoxazoles and benzisothiazoles as estrogenic agents
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
CN103083644B (zh) 2005-02-25 2014-05-28 泰特拉洛吉克药业公司 Iap二聚体抑制剂
EA200702029A1 (ru) * 2005-03-22 2008-02-28 Иннейт Фарма НОВЫЙ КЛАСС АКТИВАТОРОВ γ;δ Т-КЛЕТОК И ИХ ПРИМЕНЕНИЕ
US8362075B2 (en) * 2005-05-17 2013-01-29 Merck Sharp & Dohme Corp. Cyclohexyl sulphones for treatment of cancer
JP2008542301A (ja) 2005-05-26 2008-11-27 メタバシス・セラピューティクス・インコーポレイテッド 脂肪性肝疾患の処置のための甲状腺ホルモン様薬剤
JP2008546751A (ja) * 2005-06-22 2008-12-25 アステックス・セラピューティクス・リミテッド 医薬組成物
US8541461B2 (en) * 2005-06-23 2013-09-24 Astex Therapeutics Limited Pharmaceutical combinations comprising pyrazole derivatives as protein kinase modulators
ITRM20050344A1 (it) * 2005-06-30 2007-01-01 Luca Maria De Sali o complessi di sostanze metil-donatrici con acido fitico o suoi derivati e relativo metodo di sintesi.
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
CA2618057A1 (en) * 2005-08-11 2007-02-22 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
JP2009506007A (ja) * 2005-08-25 2009-02-12 エフ．ホフマン−ラ ロシュ アーゲー ｐ３８ＭＡＰキナーゼ阻害剤及びその使用方法
EP1919914A2 (en) * 2005-08-25 2008-05-14 F.Hoffmann-La Roche Ag P38 map kinase inhibitors and methods for using the same
CN102311385B (zh) * 2005-09-14 2015-01-14 参天制药株式会社 具有糖皮质激素受体结合活性的1,2-二氢喹啉衍生物
WO2007031977A2 (en) * 2005-09-16 2007-03-22 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b]pyridines as phosphodiesterase inhibitors
WO2007031838A1 (en) 2005-09-16 2007-03-22 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
ES2383090T3 (es) * 2005-10-12 2012-06-18 Vertex Pharmaceuticals, Inc. Derivados de bifenilo como moduladores de los canales iónicos dependientes de voltaje
CN101331120A (zh) * 2005-10-13 2008-12-24 史密丝克莱恩比彻姆公司 作为阿片样物质受体调节剂的酚醚化合物
JP5134548B2 (ja) 2005-11-15 2013-01-30 アレイ バイオファーマ、インコーポレイテッド 過剰増殖性疾患の処置のためのＥｒｂＢＩ型受容体チロシンキナーゼ阻害剤としてのＮ４−フェニルキナゾリン−４−アミン誘導体および関連化合物
UA94921C2 (en) * 2005-12-08 2011-06-25 Новартис Аг 1-orthofluorophenyl substituted 1, 2, 5-thiazolidinedione derivatives as ptp-as inhibitors
CA2636696A1 (en) * 2006-01-13 2007-08-02 Pharmacyclics, Inc. Inhibitors of tyrosine kinases and uses thereof
MY151835A (en) * 2006-01-31 2014-07-14 Array Biopharma Inc Kinase inhibitors and methods of use thereof
US8541406B2 (en) * 2006-02-07 2013-09-24 Nv Remynd Thiadiazole derivatives for the treatment of neurodegenerative diseases
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
BRPI0711558A2 (pt) 2006-05-04 2011-11-08 Boeringer Ingelheim Internat Gmbh polimorfos
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
WO2008005651A2 (en) * 2006-06-08 2008-01-10 Decode Chemistry, Inc. Cyclic carboxylic acid rhodanine derivatives for the treatment and prevention of tuberculosis
US7727978B2 (en) * 2006-08-24 2010-06-01 Bristol-Myers Squibb Company Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors
WO2008032164A2 (en) * 2006-09-12 2008-03-20 Pfizer Products Inc. Benzimidazolone derivatives
HUE028503T2 (en) 2006-09-25 2016-12-28 Ptc Therapeutics Inc Crystalline Forms of 3- [5- (2-Fluorophenyl) - [1,2,4] oxadiazol-3-yl] benzoic acid
WO2008059866A1 (fr) * 2006-11-14 2008-05-22 Santen Pharmaceutical Co., Ltd. Nouveau dérivé 1,2-dihydroquinoline comprenant un groupe alkyle inférieur à substitution phénylamino et un groupe phényle dans lequel est introduit un ester en tant que substituants
TW200831085A (en) * 2006-12-13 2008-08-01 Merck & Co Inc Non-nucleoside reverse transcriptase inhibitors
DE102007009494A1 (de) * 2007-02-27 2008-08-28 Bayer Healthcare Ag Substituierte 4-Aryl-1, 4-dihydro-1,6-naphthyridinamide und ihre Verwendung
WO2008112164A2 (en) 2007-03-08 2008-09-18 The Board Of Trustees Of The Leland Stanford Junior University Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof
US8030344B2 (en) * 2007-03-13 2011-10-04 Methylgene Inc. Inhibitors of histone deacetylase
GB0704932D0 (en) 2007-03-14 2007-04-25 Astex Therapeutics Ltd Pharmaceutical compounds
JP5538907B2 (ja) * 2007-03-23 2014-07-02 アボット ゲーエムベーハー ウント カンパニー カーゲー セロトニン５−ｈｔ６受容体の調節に応答する障害を治療する上で好適なキノリン化合物
EP2952186A1 (en) * 2007-03-26 2015-12-09 University Of Southern California Compositions for inducing apoptosis by stimulating ER stress
CN104800210B (zh) 2007-04-27 2019-08-06 锡德克斯药物公司 包含氯吡格雷和磺基烷基醚环糊精的制剂和其使用方法
EP2011786A1 (en) * 2007-07-05 2009-01-07 Laboratorios del Dr. Esteve S.A. Indane-amine derivatives, their preparation and use as medicaments
DE102007032347A1 (de) * 2007-07-11 2009-01-15 Bayer Healthcare Ag Aminoacyl-Prodrugs
US8202899B2 (en) * 2007-07-25 2012-06-19 Array Biopharma Inc. Pyrazole urea derivatives used as kinase inhibitors
US8227492B2 (en) * 2007-08-07 2012-07-24 Cadila Healthcare Limited Sulfoxamine derivatives as factor Xa inhibitors
TW200908984A (en) * 2007-08-07 2009-03-01 Piramal Life Sciences Ltd Pyridyl derivatives, their preparation and use
WO2009026579A1 (en) * 2007-08-23 2009-02-26 Cornell Research Foundation, Inc. Proteasome inhibitors and their use in treating pathogen infection and cancer
WO2009036275A1 (en) * 2007-09-13 2009-03-19 Link Medicine Corporation Treatment of neurodegenerative diseases using indatraline analogs
US10646508B1 (en) * 2007-09-18 2020-05-12 Thermolife International, Llc Method of safely administering nitrate dietary supplements and compositions
US10435356B1 (en) 2007-09-18 2019-10-08 Thermolife International, Llc Amino acid compositions
US8466187B2 (en) 2007-09-18 2013-06-18 Thermolife International, Llc Amino acid compositions
US10426750B1 (en) 2007-09-18 2019-10-01 Thermolife International, Llc Amino acid supplement formulations
JP2011503232A (ja) 2007-11-20 2011-01-27 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 免疫応答の調節
US20120142766A1 (en) * 2007-11-21 2012-06-07 Evolva Sa Substituted 1,3-dioxanes and their uses
FR2924712B1 (fr) * 2007-12-06 2012-12-21 Univ Maine Derives du gossypol et de l'apogossypol, leurs preparations et leurs applications
EP2070929A1 (en) 2007-12-11 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Alkynylaryl compounds and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
AR069650A1 (es) * 2007-12-14 2010-02-10 Actelion Pharmaceuticals Ltd Derivados de aminopirazol como agonistas no peptidicos del receptor alx humano
US20090162351A1 (en) * 2007-12-21 2009-06-25 Depuy Spine, Inc. Transdiscal administration of inhibitors of p38 MAP kinase
US8986696B2 (en) * 2007-12-21 2015-03-24 Depuy Mitek, Inc. Trans-capsular administration of p38 map kinase inhibitors into orthopedic joints
WO2009108499A1 (en) * 2008-02-25 2009-09-03 Merck & Co., Inc. Tetrahydro-1h-pyrrolo fused pyridones
EP2265609B1 (en) * 2008-02-29 2012-09-05 Array Biopharma, Inc. Imdizo [4. 5-b] pyridine derivatives used as raf inhibitors
PT2105164E (pt) * 2008-03-25 2011-03-24 Affectis Pharmaceuticals Ag Novos antagonistas de p2x7r e a sua utilização
US20090246234A1 (en) * 2008-04-01 2009-10-01 Benjamin Johnson Therapeutic Treatment Using Niacin for Skin Disorders
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
EP2116539A1 (en) 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof
EP2303273A1 (en) * 2008-05-26 2011-04-06 Medizinische Universität Innsbruck Medical intervention in haematological cancers
EP2318419B2 (en) 2008-06-17 2024-10-30 Takeda Pharmaceutical Company Limited Boronate ester compounds and pharmaceutical compositions thereof
US8524747B2 (en) * 2008-06-25 2013-09-03 Keio University Pharmaceutical compositions
CA2732765A1 (en) * 2008-08-06 2010-02-11 Vertex Pharmaceuticals Incorporated Aminopyridine kinase inhibitors
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
JP2012502048A (ja) 2008-09-08 2012-01-26 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ アルデヒドデヒドロゲナーゼ活性のモジュレーターおよびその使用方法
MX2011002558A (es) 2008-09-10 2011-04-26 Boehringer Ingelheim Int Terapia de combinacion para el tratamiento de diabetes y estados relacionados.
KR100905419B1 (ko) * 2008-09-11 2009-07-02 연세대학교 산학협력단 세스퀴테르펜 유도체의 용도
EP3023097A1 (en) * 2008-10-01 2016-05-25 Novartis AG Smoothened antagonism for the treatment of hedgehog pathway-related disorders
EP2351559B1 (en) * 2008-10-09 2015-08-12 Newtree Co., Ltd. Novel use of panduratin derivative or boesenbergia pandurata extract
AR074797A1 (es) * 2008-10-10 2011-02-16 Japan Tobacco Inc Compuesto de fluoreno , composiciones farmaceuticas , inhibidores de pdhk y pdhk2 , metodos de tratamiento , usos de los mismos y kit comercial
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
JP2012506856A (ja) * 2008-10-28 2012-03-22 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ アルデヒドデヒドロゲナーゼのモジュレーターおよびその使用方法
DE102008059133A1 (de) * 2008-11-26 2010-05-27 Merck Patent Gmbh Difluorphenyl-diacylhydrazid-derivate
KR20100060189A (ko) * 2008-11-27 2010-06-07 국립암센터 에타크리닉 산을 포함하는 트란스글루타미나제 관련 질환 예방 또는 치료용 조성물 및 그를 이용하는 트란스글루타미나제 관련 질환 예방 또는 치료 방법
US8362080B2 (en) * 2008-12-18 2013-01-29 Baylor College Of Medicine Increasing glutathione levels for therapy
TWI432188B (zh) * 2008-12-19 2014-04-01 Merz Pharma Gmbh & Co Kgaa 供治療發炎性皮膚疾病之１－胺基－烷基環己烷衍生物類
AU2009331471B2 (en) 2008-12-23 2015-09-03 Boehringer Ingelheim International Gmbh Salt forms of organic compound
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
AU2010203413B2 (en) * 2009-01-12 2015-05-14 Biokier Inc. Composition and method for treatment of diabetes
US9314444B2 (en) * 2009-01-12 2016-04-19 Biokier, Inc. Composition and method for treatment of NASH
US9006288B2 (en) 2009-01-12 2015-04-14 Biokier, Inc. Composition and method for treatment of diabetes
WO2010081488A1 (en) * 2009-01-15 2010-07-22 Humanitas Mirasole S.P.A. Nitric oxide furoxan derivative compounds endowed with antitumoral activity
WO2010084160A1 (en) 2009-01-21 2010-07-29 Oryzon Genomics S.A. Phenylcyclopropylamine derivatives and their medical use
US20100204329A1 (en) * 2009-02-06 2010-08-12 Mcfaul William J Method of using and establishing an absorption rate level and a neuron firing level
WO2010093601A1 (en) * 2009-02-10 2010-08-19 Metabasis Therapeutics, Inc. Novel sulfonic acid-containing thyromimetics, and methods for their use
ES2345241B1 (es) 2009-03-16 2011-09-08 Lipopharma Therapeutics Uso de 2-hidroxiderivados de acidos grasos poliinsaturados como medicamentos.
US8569512B2 (en) * 2009-03-23 2013-10-29 Merck Sharp & Dohme Corp. P2X3 receptor antagonists for treatment of pain
RU2553392C2 (ru) * 2009-05-07 2015-06-10 Грюненталь Гмбх Замещенные фенилмочевины и фениламиды в качестве лигандов ваниллоидных рецепторов
US8946204B2 (en) 2009-05-07 2015-02-03 Gruenenthal Gmbh Substituted phenylureas and phenylamides as vanilloid receptor ligands
HUE047755T2 (hu) 2009-05-13 2020-05-28 Cydex Pharmaceuticals Inc Prasugrelt és ciklodextrin-származékokat tartalmazó gyógyszerkészítmények, eljárás ezek elõállítására és alkalmazásra
JP5634510B2 (ja) 2009-06-12 2014-12-03 ユナイテッド セラピューティクス コーポレイション イミノ糖ならびにブニヤウイルスおよびトガウイルス疾患を治療する方法
US8283372B2 (en) 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
KR20120089459A (ko) * 2009-08-24 2012-08-10 에즈셉피온 파마슈티컬즈, 인코포레이티드 키나제 저해제로서 5,6-바이사이클릭 헤테로아릴-함유 우레아 화합물
WO2011032320A1 (en) * 2009-09-21 2011-03-24 F. Hoffmann-La Roche Ag Novel alkene oxindole derivatives
US20130072427A1 (en) * 2009-09-23 2013-03-21 Pfizer Inc. Gpr 119 modulators
EP2480528B1 (en) 2009-09-25 2018-08-29 Oryzon Genomics, S.A. Lysine specific demethylase-1 inhibitors and their use
US8946296B2 (en) 2009-10-09 2015-02-03 Oryzon Genomics S.A. Substituted heteroaryl- and aryl-cyclopropylamine acetamides and their use
NZ599298A (en) 2009-11-27 2014-11-28 Boehringer Ingelheim Int Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
JP2013518097A (ja) * 2010-01-26 2013-05-20 イッサム リサーチ ディヴェロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム エルティーディー 肺高血圧を予防および治療するための組成物および方法
US8563610B2 (en) * 2010-02-04 2013-10-22 Rutgers, The State of New Jersey Polyunsaturated fatty acids interactions and oxidative stress disorders
EP2353591A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof
BR112012020271A2 (pt) 2010-02-11 2017-08-29 Univ Vanderbilt Benzisoxazóis e azabenzisoxazóis como potencializadores alostéricos de mglur4 composições e métodos de tratamentos de disfunção neurológica
PL2534150T3 (pl) 2010-02-12 2017-09-29 Chimerix, Inc. Sposoby leczenia infekcji wirusowej
WO2011106106A2 (en) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae
US9616058B2 (en) 2010-02-24 2017-04-11 Oryzon Genomics, S.A. Potent selective LSD1 inhibitors and dual LSD1/MAO-B inhibitors for antiviral use
CA2789895C (en) 2010-03-08 2019-04-09 Spectrum Pharmaceuticals, Inc. Thioxanthone-based autophagy inhibitor therapies to treat cancer
EP2560947B1 (en) * 2010-04-19 2016-10-12 Oryzon Genomics, S.A. Lysine specific demethylase-1 inhibitors and their use
US20130231360A1 (en) * 2010-04-22 2013-09-05 The Brigham And Women S Hospital, Inc. Beta-Carbolines as Inhibitors of Haspin and DYRK Kinases
US9278135B2 (en) 2010-04-26 2016-03-08 Chimerix Inc. Methods of treating retroviral infections and related dosage regimes
US20130035332A1 (en) * 2010-04-29 2013-02-07 Layton Mark E Substituted 1,3-Benzothiazol-2(3H)-Ones and [1,3]Thiazolo[5,4-B]Pyridin-2(IH)-Ones as Positive Allosteric Modulators of MGLUR2
MX366325B (es) 2010-05-05 2019-07-05 Boehringer Ingelheim Int Terapia de combinacion.
GB201008005D0 (en) * 2010-05-13 2010-06-30 Sentinel Oncology Ltd Pharmaceutical compounds
EP2569273B1 (en) * 2010-05-14 2018-04-04 Agency For Science, Technology And Research Novel antimicrobial compounds and uses thereof
EP2388005A1 (en) 2010-05-21 2011-11-23 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
WO2011149862A1 (en) * 2010-05-27 2011-12-01 Targacept, Inc. Nicotinic receptor non-competitive antagonists modulators
GB201010359D0 (en) * 2010-06-21 2010-08-04 Univ Nottingham Compounds for treating proliferative disorders
EP3366304B1 (en) 2010-06-24 2020-05-13 Boehringer Ingelheim International GmbH Diabetes therapy
US8592427B2 (en) * 2010-06-24 2013-11-26 Alkermes Pharma Ireland Limited Prodrugs of NH-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
TW201204733A (en) * 2010-06-25 2012-02-01 Kowa Co Novel condensed pyridine or condensed pyrimidine derivative, and medicinal agent comprising same
US8846671B2 (en) * 2010-07-01 2014-09-30 Guangzhou Institute Of Biomedicine And Health, Chinese Academy Of Sciences Heterocyclic alkynyl benzene compounds and medical compositions and uses thereof
CA2805015A1 (en) * 2010-07-13 2012-01-19 Stuart Ince Bicyclic pyrimidines
CN103384670B (zh) 2010-07-28 2016-05-25 拜耳知识产权有限责任公司 取代的咪唑并[1,2-b]哒嗪
CN104892525A (zh) 2010-07-29 2015-09-09 奥瑞泽恩基因组学股份有限公司 Lsd1的基于芳基环丙胺的脱甲基酶抑制剂及其医疗用途
EP2598480B1 (en) 2010-07-29 2019-04-24 Oryzon Genomics, S.A. Cyclopropylamine derivatives useful as lsd1 inhibitors
BR112013003481A8 (pt) * 2010-07-29 2017-12-26 Astellas Pharma Inc composto fundido a anel de piridina
EP2415471A1 (en) 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in opioid-induced hyperalgesia
PL392436A1 (pl) * 2010-09-17 2012-03-26 Adamed Spółka Z Ograniczoną Odpowiedzialnością Pochodne arylosulfonamidów do leczenia chorób odśrodkowego układu nerwowego
US8829026B2 (en) * 2010-10-01 2014-09-09 Raqualia Pharma Inc. Sulfamoyl benzoic acid heterobicyclic derivatives as TRPM8 antagonists
US9061966B2 (en) 2010-10-08 2015-06-23 Oryzon Genomics S.A. Cyclopropylamine inhibitors of oxidases
CN103298791B (zh) * 2010-10-20 2016-02-03 生物科学管理有限责任公司 病毒聚合酶抑制剂
TWI537258B (zh) * 2010-11-05 2016-06-11 百靈佳殷格翰國際股份有限公司 六氫茚并吡啶及八氫苯并喹啉之芳基－及雜環芳基羰基衍生物
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
ES2594404T3 (es) * 2010-11-24 2016-12-20 Merck Patent Gmbh Quinazolincarboxamida azetidinas
WO2012072713A2 (en) 2010-11-30 2012-06-07 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae
WO2012075242A2 (en) * 2010-12-01 2012-06-07 Washington State University Research Foundation Controlled chemical release of hydrogen sulfide
US11974971B2 (en) 2011-01-07 2024-05-07 Anji Pharmaceuticals Inc. Compositions and methods for treating metabolic disorders
US9480663B2 (en) 2011-01-07 2016-11-01 Elcelyx Therapeutics, Inc. Biguanide compositions and methods of treating metabolic disorders
US9572784B2 (en) 2011-01-07 2017-02-21 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
CN103597071A (zh) 2011-01-07 2014-02-19 埃尔舍利克斯治疗公司 基于化学感应受体配体的治疗
US9211263B2 (en) 2012-01-06 2015-12-15 Elcelyx Therapeutics, Inc. Compositions and methods of treating metabolic disorders
US8796338B2 (en) 2011-01-07 2014-08-05 Elcelyx Therapeutics, Inc Biguanide compositions and methods of treating metabolic disorders
WO2013103384A1 (en) 2012-01-06 2013-07-11 Elcelyx Therapeutics, Inc. Biguanide compositions and methods of treating metabolic disorders
US11759441B2 (en) 2011-01-07 2023-09-19 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
ES2610362T3 (es) * 2011-01-25 2017-04-27 Viviabiotech, S.L. Derivados de 1,2,4-oxadiazol como fármacos moduladores del receptor para el péptido glp-1
EP2712315B1 (en) 2011-02-08 2021-11-24 Oryzon Genomics, S.A. Lysine demethylase inhibitors for myeloproliferative disorders
US20120208872A1 (en) * 2011-02-11 2012-08-16 Taipei Medical University Use of tea polyphenols for treating and/or preventing nicotine or nicotine-derived compounds or estrogen induced breast cancer
PE20140859A1 (es) * 2011-02-25 2014-07-25 Merck Sharp & Dohme Novedosos derivados de azabencimidazol ciclico utiles como agentes antidiabeticos
US8642655B2 (en) * 2011-03-09 2014-02-04 Benjamin Johnson Systems and methods for preventing cancer and treating skin lesions
UA109931C2 (xx) * 2011-03-18 2015-10-26 Піримідинциклогексильні модулятори глюкокортикоїдних рецепторів
WO2012127466A1 (en) * 2011-03-24 2012-09-27 Bar Ilan University 5-aminolevulinic acid derivatives, methods for their preparation and uses thereof
US8791112B2 (en) * 2011-03-30 2014-07-29 Arrien Pharmaceuticals Llc Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3, 4-B] pyridine and pyrazolo [3, 4-B] pyridine derivatives as protein kinase inhibitors
US8802731B2 (en) 2011-04-13 2014-08-12 Thermolife International, Llc N-acetyl beta alanine methods of use
ES2617215T3 (es) * 2011-04-19 2017-06-15 Daiichi Sankyo Company, Limited Derivado de tetrahirotiazepina
US10457659B2 (en) 2011-04-29 2019-10-29 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
EP2524694A1 (en) * 2011-05-19 2012-11-21 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in diabetes type-2 associated pain
US8487008B2 (en) * 2011-06-22 2013-07-16 Universita Degli Studi Di Padova Treatment of muscular dystrophies and associated conditions by administration of monoamine oxidase inhibitors
WO2012177263A1 (en) * 2011-06-24 2012-12-27 Intra-Cellular Therapies, Inc. Compounds and methods of prophylaxis and treatment regarding nictonic receptor antagonists
US8658677B2 (en) * 2011-07-07 2014-02-25 Aria Neurosciences Inc. Pyridyl-2-methylamino compounds, compositions and uses thereof
PL3517539T3 (pl) 2011-07-15 2023-04-24 Boehringer Ingelheim International Gmbh Podstawiona dimeryczna pochodna chinazoliny, sposób jej wytwarzania i jej zastosowanie w kompozycjach farmaceutycznych do leczenia cukrzycy typu I i II
TW201311679A (zh) * 2011-08-04 2013-03-16 Takeda Pharmaceutical 含氮雜環化合物
UA113291C2 (xx) 2011-08-04 2017-01-10 Метаболіти транскломіфену і їх застосування
WO2013028543A1 (en) * 2011-08-19 2013-02-28 Emory University Bax agonist, compositions, and methods related thereto
EP2766366B1 (en) * 2011-09-14 2016-11-09 Chiesi Farmaceutici S.p.A. Tetrahydrotriazolopyrimidine derivatives as human neutrophil elastase inhbitors
PE20141678A1 (es) 2011-09-14 2014-11-21 Samumed Llc Indazol-3-carboxamidas y su uso como inhibidores de la ruta de senalizacion de wnt/b-catenina
EP2760835A1 (en) 2011-09-26 2014-08-06 Grünenthal GmbH Aryl or n-heteroaryl substituted methanesulfonamide derivatives as vanilloid receptor ligands
AR088003A1 (es) * 2011-09-26 2014-04-30 Gruenenthal Gmbh Derivados de metansulfonamida sustituidos con amina como ligandos del receptor de vanilloide
AU2012324805B2 (en) 2011-10-20 2017-04-13 Oryzon Genomics, S.A. (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
US9487512B2 (en) 2011-10-20 2016-11-08 Oryzon Genomics S.A. (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
JP5769889B2 (ja) 2011-10-26 2015-08-26 ケムファーム・インコーポレーテッド ヒドロモルホンの安息香酸、安息香酸誘導体及びヘテロアリールカルボン酸結合体、そのプロドラッグ、製造法及び使用
US9163032B2 (en) * 2011-11-13 2015-10-20 Blanchette Rockefeller Neurosciences Insitute Esters of DCPLA and methods of treatment using the same
EP2782994B1 (en) 2011-11-22 2017-05-10 Trustees Of Tufts College Small molecule enhancer for dendritic cell cancer vaccines
CA2857109A1 (en) * 2011-12-05 2013-06-13 Glenmark Pharmaceuticals S.A. Pharmaceutical composition comprising a trpa1 antagonist and an anticholinergic agent
EP2800562A2 (en) 2012-01-06 2014-11-12 Elcelyx Therapeutics, Inc. Compositions and methods for treating metabolic disorders
CN102603493B (zh) * 2012-01-17 2014-03-12 青岛农业大学 含氟邻烯丙基苯酚类化合物的制备方法及农用生物活性
CN104114162A (zh) * 2012-02-14 2014-10-22 利普生物药剂公司 具有短半衰期的选择性雌激素受体调节剂及其用途
CN102614177B (zh) * 2012-03-06 2014-08-06 北京伟峰益民科技有限公司 卢帕他定在制备治疗慢性阻塞性肺病药物组合物中的应用
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US9238015B2 (en) * 2012-03-30 2016-01-19 Nestec S.A. 4-oxo-2-pentenoic acid and cardiovascular health
EP2847165A2 (en) * 2012-04-02 2015-03-18 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Indole, indoline derivatives, compositions comprising them and uses thereof
PH12017500997A1 (en) 2012-04-04 2018-02-19 Samumed Llc Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
BR112014023670A8 (pt) * 2012-04-04 2017-07-25 Chiesi Farm Spa Composto, composição farmacêutica e suo de um composto
US8809376B2 (en) * 2012-04-30 2014-08-19 Boehringer Ingelheim International Gmbh Indanyloxydihydrobenzofuranylacetic acids
US20130303462A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
US12226412B2 (en) 2012-05-25 2025-02-18 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
US20130345205A1 (en) * 2012-06-20 2013-12-26 Vanderbilt University Substituted bicyclic aralkyl pyrazole lactam analogs as allosteric modulators of mglur5 receptors
EP2863922A4 (en) * 2012-06-20 2015-11-04 Univ Vanderbilt SUBSTITUTED BICYCLIC ALKOXYPYRAZOL ANALOGUES AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS
CA2879431A1 (en) 2012-07-17 2014-01-23 Washington University Anti-mucus drugs and uses therefor
ES2941477T3 (es) * 2012-08-13 2023-05-23 Univ Rockefeller Agonista de LXRbeta para el tratamiento de cáncer
CA3139033A1 (en) 2012-08-22 2014-02-27 Cornell University Methods for inhibiting fascin
CN104602690A (zh) * 2012-08-29 2015-05-06 默克专利股份有限公司 用于治疗骨关节炎的ddr2抑制剂
US8859598B2 (en) * 2012-10-04 2014-10-14 Allergan, Inc. 1, 2, 4-oxadiazoles azetidine derivatives as sphingosine-1 phosphate receptors modulators
US9278081B2 (en) * 2012-10-04 2016-03-08 University Of The West Indies Extracts from Eucalyptus camaldulensis for the treatment of hyperglycemia and hypertension
MX2015005160A (es) 2012-11-02 2015-07-17 Repros Therapeutics Inc Trans-clomifeno para uso en terapia de cancer.
US9624214B2 (en) 2012-11-05 2017-04-18 Bayer Pharma Aktiengesellschaft Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
US9163027B2 (en) * 2012-11-21 2015-10-20 Stategics, Inc. Substituted triazolo-pyrimidine compounds for modulating cell proliferation differentiation and survival
BR112015012716A2 (pt) * 2012-12-05 2017-07-11 Chiesi Farm Spa derivados de feniletilpiridina como inibidores de pde4
JP6283862B2 (ja) 2012-12-07 2018-02-28 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規インダニルオキシジヒドロベンゾフラニル酢酸
UY35212A (es) * 2012-12-21 2014-06-30 Gilead Sciences Inc Inhibidores de la quinasa que regula la señal de la apoptosis
CN105120862A (zh) 2013-01-08 2015-12-02 萨穆梅德有限公司 Wnt信号途径的3-(苯并咪唑-2-基)-吲唑抑制剂及其治疗应用
CU20130027A7 (es) * 2013-02-28 2014-10-30 Ct De Neurociencias De Cuba Chaperoninas químicas como nuevos moduladores moleculares de la beta agregación proteica presente en las enfermedades conformacionales
SI2970132T1 (sl) 2013-03-14 2021-02-26 Epizyme, Inc. Inhibitorji argininmetiltransferaze in njihove uporabe
EP2970136A1 (en) 2013-03-14 2016-01-20 Epizyme, Inc. Arginine methyl transferase inhibtors and uses thereof
US9120757B2 (en) 2013-03-14 2015-09-01 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
WO2014144659A1 (en) 2013-03-14 2014-09-18 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
WO2014153172A1 (en) 2013-03-14 2014-09-25 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
WO2014153208A1 (en) 2013-03-14 2014-09-25 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
US9765035B2 (en) 2013-03-14 2017-09-19 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
US9776972B2 (en) 2013-03-14 2017-10-03 Epizyme Inc. Pyrazole derivatives as arginine methyltransferase inhibitors and uses thereof
EP2970124B1 (en) 2013-03-14 2019-05-22 The Board of Trustees of the Leland Stanford Junior University Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof
WO2014151258A1 (en) 2013-03-15 2014-09-25 Janssen Pharmaceutica Nv Substituted pyridine derivatives useful as c-fms kinase inhibitors
US20140335079A1 (en) * 2013-05-07 2014-11-13 Emory University Solenopsin and derivatives, therapeutic compositions, and methods related thereto
JP5740062B1 (ja) * 2013-07-03 2015-06-24 三菱化学フーズ株式会社 毛状疣贅病の予防および／または治療方法
SG11201600241RA (en) * 2013-07-18 2016-02-26 Novartis Ag Autotaxin inhibitors comprising a heteroaromatic ring-benzyl-amide-cycle core
US20150045435A1 (en) * 2013-08-06 2015-02-12 Indiana University Research And Technology Corporation Compounds and methods for treating diabetes
EP3035921A1 (en) * 2013-08-20 2016-06-29 Bristol-Myers Squibb Company Imidazopyridazine kinase inhibitors useful to treating a disease or disorder mediated by aak1, such as alzheimer's disease, bipolar disorder, pain, schizophrenia
WO2015027160A2 (en) * 2013-08-22 2015-02-26 Northeastern University Allosteric modulators of the cannibinoid 1 receptor
JP2016530333A (ja) 2013-09-13 2016-09-29 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー 放射線の影響から防護するため及び放射線の影響を緩和するための組成物の調製及び使用
US9353078B2 (en) * 2013-10-01 2016-05-31 New York University Amino, amido and heterocyclic compounds as modulators of rage activity and uses thereof
KR102096796B1 (ko) * 2013-10-22 2020-05-27 샤이어 휴먼 지네틱 테라피즈 인크. 메신저 rna의 전달을 위한 지질 제형
HUE038636T2 (hu) * 2013-12-13 2018-12-28 Daiichi Sankyo Co Ltd 5-Hidroxi-4-(trifluormetil)pirazolopiridin származék
EP3082782A1 (en) 2013-12-17 2016-10-26 Laboratorios Del. Dr. Esteve, S.A. SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIs) AND SIGMA RECEPTOR LIGANDS COMBINATIONS
US9381171B2 (en) * 2013-12-19 2016-07-05 Samsung Electronics Co., Ltd. Composition including dapsone for preventing or treating side effect of steroid in subject and use of the composition
US9862704B2 (en) * 2013-12-20 2018-01-09 AbbVie Deutschland GmbH & Co. KG Oxindole derivatives carrying an amine-substituted piperidyl-acetidinyl substituent and use thereof for treating vasopressine-related diseases
CN104744446B (zh) * 2013-12-30 2019-06-25 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
AU2015204572B2 (en) 2014-01-10 2020-07-30 Inspirna, Inc. LXR agonists and uses thereof
US9636298B2 (en) 2014-01-17 2017-05-02 Methylgene Inc. Prodrugs of compounds that enhance antifungal activity and compositions of said prodrugs
DK3107902T3 (da) * 2014-02-20 2021-05-03 Cornell Univ Cornell Center For Technology Enterprise & Commercialization Cctec Forbindelser og fremgangsmåder til at hæmme fascin
TWI672141B (zh) 2014-02-20 2019-09-21 美商醫科泰生技 投予ｒｏｓ１突變癌細胞之分子
WO2015128453A1 (en) 2014-02-28 2015-09-03 Boehringer Ingelheim International Gmbh Medical use of a dpp-4 inhibitor
US9771360B2 (en) 2014-03-21 2017-09-26 Bayer Pharma Aktiengesellschaft Cyano-substituted imidazo[1,2-A]pyridinecarboxamides and their use
AU2015264272A1 (en) 2014-05-20 2016-11-24 Millennium Pharmaceuticals, Inc. Boron-containing proteasome inhibitors for use after primary cancer therapy
US10300042B2 (en) 2014-06-23 2019-05-28 Celgene Corporation Apremilast for the treatment of a liver disease or a liver function abnormality
WO2016040190A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
WO2016040193A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
WO2016040184A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040181A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040185A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof
WO2016040180A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
TW201615224A (zh) * 2014-10-24 2016-05-01 朗齊生物醫學股份有限公司 消化系統疾病用藥臨床新應用
EP3215140A4 (en) * 2014-11-06 2018-05-02 The Arizona Board of Regents On Behalf of the University of Arizona Compositions and methods of diazeniumdiolate-based prodrugs for treating cancer
EP3215144B1 (en) * 2014-11-07 2021-04-28 Northwestern University Ornithine aminotransferase inhibition with gaba analogues for treatment of hepatocellular carcinoma
WO2016089951A1 (en) * 2014-12-02 2016-06-09 Kempharm, Inc. Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxymorphone, prodrugs, methods and making and use thereof
CA2969268A1 (en) 2014-12-02 2016-06-09 Bayer Pharma Aktiengesellschaft Heteroaryl-substituted imidazo[1,2-a]pyridines and their use
KR102595599B1 (ko) 2014-12-02 2023-11-02 이그니타, 인코포레이티드 신경모세포종의 치료를 위한 병용
EP3226869A4 (en) * 2014-12-03 2018-07-18 Auckland UniServices, Ltd. Kinase inhibitor prodrug for the treatment of cancer
WO2016094854A2 (en) * 2014-12-12 2016-06-16 Miradx Methods for treating or preventing cancer in a kras-variant patient and for diagnosing risk of developing multiple primary breast tumors
ES2961334T3 (es) 2015-01-22 2024-03-11 Mitochon Pharmaceuticals Inc Expresión inducida del factor neurotrófico derivado del cerebro (BDNF) para el tratamiento de enfermedades neuromusculares y/o neurodegenerativas
KR20230173743A (ko) * 2015-03-04 2023-12-27 반다 파마슈티칼즈, 인코퍼레이티드. 트라디피턴트에 의한 치료 방법
US20180071376A1 (en) 2015-03-23 2018-03-15 The Brigham And Women`S Hospital, Inc. Tolerogenic nanoparticles for treating diabetes mellitus
EA201792304A1 (ru) * 2015-04-20 2018-03-30 Эпизайм, Инк. Комбинированная терапия для лечения рака
EP3288933B1 (en) * 2015-04-30 2021-10-06 Musc Foundation for Research Development Oxindole compounds and pharmaceutical compositions thereof
US20160324914A1 (en) 2015-05-05 2016-11-10 Tocol Pharmaceuticals, Llc Use of rice bran oil distillate extract for prevention and mitigation of the effects of radiation
TWI713534B (zh) 2015-06-11 2020-12-21 日商第一三共股份有限公司 5-羥基-4-(三氟甲基)吡唑并吡啶衍生物之結晶及其用途
GB201511382D0 (en) 2015-06-29 2015-08-12 Imp Innovations Ltd Novel compounds and their use in therapy
WO2017024026A1 (en) 2015-08-03 2017-02-09 Samumed, Llc 3-(1h-indol-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
US10188634B2 (en) 2015-08-03 2019-01-29 Samumed, Llc 3-(3H-imidazo[4,5-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
US10285983B2 (en) 2015-08-03 2019-05-14 Samumed, Llc 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-B] pyridines and therapeutic uses thereof
US10519169B2 (en) 2015-08-03 2019-12-31 Samumed, Llc 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
US10604512B2 (en) 2015-08-03 2020-03-31 Samumed, Llc 3-(1H-indol-2-yl)-1H-indazoles and therapeutic uses thereof
US10383861B2 (en) 2015-08-03 2019-08-20 Sammumed, LLC 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
US10195185B2 (en) 2015-08-03 2019-02-05 Samumed, Llc 3-(1H-imidazo[4,5-C]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
US10206909B2 (en) 2015-08-03 2019-02-19 Samumed, Llc 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
US10226448B2 (en) 2015-08-03 2019-03-12 Samumed, Llc 3-(1H-pyrrolo[3,2-C]pyridin-2-yl)-1H-pyrazolo[3,4-B]pyridines and therapeutic uses thereof
WO2017023980A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
US10231956B2 (en) 2015-08-03 2019-03-19 Samumed, Llc 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
WO2017023993A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-indol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
WO2017024010A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
WO2017024015A1 (en) * 2015-08-03 2017-02-09 Samumed, Llc. 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
WO2017023984A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
WO2017024021A1 (en) 2015-08-03 2017-02-09 Samumed, Llc 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
WO2017023989A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US9675608B2 (en) * 2015-08-26 2017-06-13 Macau University Of Science And Technology Identification of natural small-molecules AMPK activators for treatment of cancers or multidrug-resistant cancers
US10450300B2 (en) * 2015-10-08 2019-10-22 Suzhou Yunxuan Yiyao Keji Youxian Gongsi Wnt signaling pathway inhibitors and therapeutic applications thereof
GB201519450D0 (en) * 2015-11-03 2015-12-16 Univ Liverpool Novel treatment
US10544139B2 (en) 2015-11-06 2020-01-28 Samumed, Llc Treatment of osteoarthritis
US9549907B1 (en) * 2015-11-13 2017-01-24 Sovereign Pharmaceuticals, Llc Immediate release oral guaifenesin solution
US10765665B2 (en) * 2015-11-24 2020-09-08 Melin Jeffrey Composition comprising combination of rapamycin and an activator of AMP kinase and use thereof for treating diseases
EP3380469B1 (en) * 2015-11-25 2022-03-16 Convergene Llc Bicyclic bet bromodomain inhibitors and uses thereof
WO2017106492A1 (en) 2015-12-18 2017-06-22 Ignyta, Inc. Combinations for the treatment of cancer
JP2019507773A (ja) * 2016-03-09 2019-03-22 ネザーランズ トランスレーショナル リサーチ センター ビー．ブイ． インドールアミン２，３−ジオキシゲナーゼの阻害剤
EP3430004B1 (en) * 2016-03-14 2020-07-15 Pliva Hrvatska D.O.O. Solid state forms of nilotinib salts
US10064834B2 (en) * 2016-05-09 2018-09-04 Texas Tech University System Carbidopa for the treatment of cancer
EP3454862B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
CN108289865B (zh) * 2016-05-26 2021-02-23 中国热带农业科学院热带生物技术研究所 诺卡酮的应用
US10072004B2 (en) 2016-06-01 2018-09-11 Samumed, Llc Process for preparing N-(5-(3-(7-(3-fluorophenyl)-3H-imidazo [4,5-C]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide
EP3251668A1 (en) * 2016-06-02 2017-12-06 Pharmotech SA Cannabidiol compositions and uses thereof
CN109310697A (zh) 2016-06-10 2019-02-05 勃林格殷格翰国际有限公司 利格列汀和二甲双胍的组合
EP3509575B1 (en) 2016-09-07 2025-03-19 Temple University Of The Commonwealth System Of Higher Education Compositions and methods for treatment of insulin resistance
EP3446704A1 (en) 2017-08-24 2019-02-27 Isofol Medical AB [6r]-mthf - an efficient folate alternative in 5-fluorouracil based chemotherapy
EP3446703A1 (en) * 2017-08-24 2019-02-27 Isofol Medical AB 6r]-mthf multiple bolus administration in 5-fluorouracil based chemotherapy
JP2019535672A (ja) 2016-10-21 2019-12-12 サミュメッド リミテッド ライアビリティ カンパニー インダゾール−３−カルボキサミドの使用方法およびｗｎｔ／β−カテニンシグナル伝達経路阻害剤としてのそれらの使用
KR102558716B1 (ko) 2016-11-07 2023-07-21 사뮤메드, 엘엘씨 단일-투여량, 즉시-사용가능한 주사용 제제
BR112019010249A2 (pt) 2016-11-21 2019-09-10 Viking Therapeutics Inc método de tratamento de doença de armazenamento de glicogênio
JP2020501502A (ja) * 2016-12-15 2020-01-23 ソシエテ・デ・プロデュイ・ネスレ・エス・アー コンパニオンアニマルにおける消化率を調節する組成物及び方法
US10723716B2 (en) 2016-12-21 2020-07-28 New York University Alpha-helix mimetics as modulators of Abeta self-assembly
US10913720B2 (en) 2017-01-26 2021-02-09 Boehringer Ingelheim International Gmbh Benzyloxypyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
CN110177773B (zh) 2017-01-26 2023-08-25 勃林格殷格翰国际有限公司 苄基氨基吡啶基环丙烷羧酸、其药物组合物及其用途
CN110248929B (zh) 2017-01-26 2023-05-12 勃林格殷格翰国际有限公司 苄基氨基吡嗪基环丙烷甲酸、其药物组合物和用途
EP3573969A1 (en) 2017-01-26 2019-12-04 Boehringer Ingelheim International GmbH Benzyloxypyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
CN110300755B (zh) 2017-02-08 2022-10-04 勃林格殷格翰国际有限公司 茚满基氨基氮杂二氢苯并呋喃乙酸、用于治疗糖尿病的药物组合物
JP7122256B2 (ja) 2017-02-14 2022-08-19 アイソフォル・メディカル・エービー 血漿２’－デオキシウリジン（ｄＵｒｄ）の増加およびチミジル酸合成酵素阻害のための方法
US10517842B2 (en) * 2017-03-15 2019-12-31 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Methods of modulating miRNA levels and compositions for use in the same
RU2675496C1 (ru) * 2017-03-31 2018-12-20 Федеральное государственное бюджетное учреждение науки Институт нефтехимии и катализа Российской академии наук Способ получения алкиловых эфиров гидроксибензойных кислот
EP3600282A4 (en) 2017-03-31 2020-08-19 Corcept Therapeutics, Inc. GLUCOCORTICOID RECEPTOR MODULATORS FOR THE TREATMENT OF COLD CANCER
US20180280319A1 (en) * 2017-04-04 2018-10-04 University Of The Sciences Compounds and compositions for treatment of breast cancer
FR3066393B1 (fr) * 2017-05-16 2019-07-19 Polyneuros Principe actif constitue par un melange de composes poly-lysine et utilisation dans la prevention des avc et le traitement de la phase inflammatoire post-avc
US11491150B2 (en) 2017-05-22 2022-11-08 Intra-Cellular Therapies, Inc. Organic compounds
AU2018280118B2 (en) 2017-06-05 2021-07-15 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis
CA3069339A1 (en) * 2017-07-19 2019-01-24 Ignyta, Inc. Pharmaceutical compositions comprising entrectinib
US10639313B2 (en) * 2017-09-01 2020-05-05 Ndsu Research Foundation Compound for inhibition of delta-5-desaturase (D5D) and treatment of cancer and inflammation
WO2019055225A1 (en) 2017-09-13 2019-03-21 Vanda Pharmaceuticals Inc. ENHANCED TREATMENT OF ATOPIC DERMATITIS USING TRADIPITANT
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
CA3078232A1 (en) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. Use of p38 inhibitors to reduce expression of dux4
JP7311498B2 (ja) 2017-10-17 2023-07-19 イグナイタ インコーポレイテッド 薬学的組成物および剤形
WO2019084323A1 (en) * 2017-10-25 2019-05-02 Georgia State University Research Foundation, Inc. CHEMICAL RELEASE SYSTEM DELIVERED BY ENRICHMENT
AU2018360059B2 (en) 2017-11-03 2023-07-13 Aclaris Therapeutics, Inc. Substituted pyrrolopyrimidine JAK inhibitors and methods of making and using the same
JP2021504315A (ja) 2017-11-21 2021-02-15 ルジェニクス，インコーポレーテッド 多形及びその使用
AU2019238090B2 (en) 2018-03-22 2024-08-01 Viking Therapeutics, Inc. Crystalline forms and methods of producing crystalline forms of a compound
CA3094324A1 (en) 2018-03-26 2019-10-03 Clear Creek Bio, Inc. Compositions and methods for inhibiting dihydroorotate dehydrogenase
ES2987563T3 (es) 2018-06-04 2024-11-15 Corcept Therapeutics Inc Moduladores del receptor de glucocorticoides ciclohexenilo pirimidina
WO2020033955A1 (en) 2018-08-10 2020-02-13 Aclaris Therapeutics, Inc. Pyrrolopyrimidine itk inhibitors
EP3853220B1 (en) 2018-09-18 2024-01-03 F. Hoffmann-La Roche AG Quinazoline derivatives as antitumor agents
US12102646B2 (en) 2018-12-05 2024-10-01 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis and inflammation
WO2020132023A1 (en) 2018-12-19 2020-06-25 Corcept Therapeutics Incorporated Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound
US11234971B2 (en) 2018-12-19 2022-02-01 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
US11389432B2 (en) 2018-12-19 2022-07-19 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
SG11202108927UA (en) 2019-05-02 2021-09-29 Aclaris Therapeutics Inc Substituted pyrrolopyridines as jak inhibitors
KR20220113767A (ko) 2019-12-11 2022-08-16 코어셉트 쎄라퓨틱스 인코포레이티드 미리코릴란트로 항정신병약-유도 체중 증가를 치료하는 방법
EP4073025B1 (en) 2019-12-13 2024-03-27 Inspirna, Inc. Metal salts and uses thereof
WO2021189018A1 (en) 2020-03-20 2021-09-23 Clear Creek Bio, Inc. Methods of treating viral infections using inhibitors of nucleotide synthesis pathways
JP7474869B2 (ja) 2020-05-06 2024-04-25 コーセプト セラピューティクス， インコーポレイテッド ピリミジンシクロヘキシルグルココルチコイド受容体モジュレーターの製剤
WO2021226260A1 (en) 2020-05-06 2021-11-11 Corcept Therapeutics Incorporated Polymorphs of pyrimidine cyclohexyl glucocorticoid receptor modulators
US11071739B1 (en) 2020-09-29 2021-07-27 Genus Lifesciences Inc. Oral liquid compositions including chlorpromazine
US11865139B2 (en) 2020-11-12 2024-01-09 Thermolife International, Llc Method of treating migraines and headaches
US12156886B2 (en) 2020-11-12 2024-12-03 Thermolife International, Llc Methods of increasing blood oxygen saturation
CN116848092A (zh) 2020-12-21 2023-10-03 科赛普特治疗公司 制备嘧啶环己基糖皮质激素受体调节剂的方法
WO2022134033A1 (en) 2020-12-25 2022-06-30 Corcept Therapeutics Incorporated Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
CN113354558B (zh) * 2021-07-12 2022-03-11 无锡双启科技有限公司 一种2-氨基-5-氟苯腈的制备方法
WO2025056518A1 (en) * 2023-09-11 2025-03-20 Univerza V Ljubljani 5,6-DISUBSTITUTED ALKYL 1H AND 2H-INDAZOLES AS DUAL BUTYRYLCHOLINESTERASE AND p38α MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE AND INFLAMMATORY DISEASES

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3755332A (en) 1971-07-01 1973-08-28 Ciba Geigy Corp Substituted 4 indazolaminoquinolines
JPS5998060A (ja) * 1982-11-27 1984-06-06 Fujisawa Pharmaceut Co Ltd インダゾ−ル誘導体、その製造法および農薬
US4571255A (en) * 1983-12-29 1986-02-18 Ppg Industries, Inc. Subsituted phenoxybenzisoxazole herbicides
GB8524157D0 (en) 1984-10-19 1985-11-06 Ici America Inc Heterocyclic amides
SU1545940A3 (ru) 1984-10-19 1990-02-23 Ай-Си-Ай Америказ Инк (Фирма) Способ получени гетероциклических кислот или их солей
US5234942A (en) 1984-10-19 1993-08-10 Ici Americas Inc. Heterocyclic amides and leucotriene antagonistic use thereof
PL265549A1 (en) 1985-03-26 1988-09-01 The method of manufacture of new heterocyclic amides
JPS6368568A (ja) * 1986-09-10 1988-03-28 Otsuka Pharmaceut Factory Inc ｐ−アミノフエノ−ル誘導体
NZ224714A (en) * 1987-06-01 1990-03-27 Janssen Pharmaceutica Nv Substituted benzotriazole derivatives and pharmaceutical compositions
IL97102A0 (en) * 1990-02-16 1992-03-29 Ici Plc Heterocyclic compounds
IE910278A1 (en) 1990-02-16 1991-08-28 Ici Plc Heterocyclic compounds
WO1992021660A1 (en) 1991-05-29 1992-12-10 Pfizer, Inc. Tricyclic polyhydroxylic tyrosine kinase inhibitors
AU662997B2 (en) 1992-07-03 1995-09-21 Ihara Chemical Industry Co. Ltd. Condensed heterocyclic derivative and weedkiller
US5587392A (en) * 1994-05-27 1996-12-24 Mochida Pharmaceutical Co., Ltd. Azolyl methyl phenyl derivatives having aromatase inhibitory activity
JPH0841032A (ja) * 1994-05-27 1996-02-13 Mochida Pharmaceut Co Ltd アロマターゼ阻害作用を有する新規なアゾールメチルフェニル誘導体
US6083949A (en) 1995-10-06 2000-07-04 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
CA2234066C (en) 1995-10-06 2005-12-13 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
IL128642A0 (en) 1996-09-04 2000-01-31 Pfizer Indazole derivatives and their use as inhibitors of phosphodiesterase (pde) type iv and the production of tumor necrosis factor (tnf)
US6809097B1 (en) 1996-09-25 2004-10-26 Zeneca Limited Quinoline derivatives inhibiting the effect of growth factors such as VEGF
ATE244714T1 (de) 1996-11-08 2003-07-15 Bristol Myers Squibb Pharma Co 1-(3-aminoindazol-5-yl)-3-phenylmethyl cyclische harnstoffe und ihre verwendung als hiv protease inhibitoren
US5932570A (en) * 1996-11-08 1999-08-03 Dupont Pharmaceuticals Company 1-(3-aminoindazol-5-yl)-3-phenylmethyl-cyclic ureas useful as HIV protease inhibitors
US6218386B1 (en) 1996-11-08 2001-04-17 Dupont Pharmaceuticals A1-(3-aminoindazol-5-yl)-3 butyl-cyclic urea useful as a HIV protease inhibitor
US5945418A (en) 1996-12-18 1999-08-31 Vertex Pharmaceuticals Incorporated Inhibitors of p38
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
IL132318A0 (en) 1997-04-24 2001-03-19 Ortho Mcneil Pharm Inc Substituted imidazoles useful in the treatment of inflammatory diseases
AU7726898A (en) 1997-05-22 1998-12-11 G.D. Searle & Co. Pyrazole derivatives as p38 kinase inhibitors
US6093742A (en) 1997-06-27 2000-07-25 Vertex Pharmaceuticals, Inc. Inhibitors of p38
US6297239B1 (en) 1997-10-08 2001-10-02 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
BR9812944A (pt) 1997-10-20 2000-08-08 Hoffmann La Roche Inibidores bicìclicos da cinase
AU1367599A (en) 1997-11-03 1999-05-24 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as anti-inflammatory agents
EA200000385A1 (ru) 1997-11-04 2000-10-30 Пфайзер Продактс Инк. Терапевтически активные соединения на основе индазольной биоизостерической замены катехина в ингибиторах фосфодиэстеразы типа vi (pde4)
BR9813926A (pt) 1997-11-04 2000-09-19 Pfizer Prod Inc Substituição de bioisóstero de catecol por indazol em compostos terapeuticamente ativos
US6329412B1 (en) 1997-11-04 2001-12-11 Pfizer Inc Bisamidine compounds as antiproliferative agents
JP2002503733A (ja) 1998-02-12 2002-02-05 ユニバーシティ・オブ・デラウェア β−ジアミンアニオン性配位子を含む触媒化合物およびオレフィンの重合方法
US6589954B1 (en) 1998-05-22 2003-07-08 Scios, Inc. Compounds and methods to treat cardiac failure and other disorders
GB9820767D0 (en) 1998-09-23 1998-11-18 Cerebrus Ltd Chemical compounds VIII
UA73492C2 (en) 1999-01-19 2005-08-15 Aromatic heterocyclic compounds as antiinflammatory agents
EP1157026A1 (en) 1999-02-22 2001-11-28 Boehringer Ingelheim Pharmaceuticals Inc. Polycyclo heterocyclic derivatives as antiinflammatory agents
EE04799B1 (et) 1999-03-12 2007-04-16 Boehringer Ingelheim Pharmaceuticals, Inc. Ühendid, mis on kasulikud põletikuvastaste vahenditena, nende ühendite valmistamise meetodid ja neid sisaldavad farmatseutilised kompositsioonid
WO2000055152A1 (en) 1999-03-12 2000-09-21 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as anti-inflammatory agents
HUP0201708A3 (en) 1999-03-29 2005-02-28 Shire Biochem Inc Laval The use of nucleoside analogues for treating leukemia
WO2000059930A1 (en) 1999-04-05 2000-10-12 Merck & Co., Inc. A method of treating cancer
KR20020002433A (ko) 1999-04-21 2002-01-09 윌리암 에이취 캘넌, 에곤 이 버그 티로신 키나제의 치환된 3-시아노-[1.7],[1.5] 및[1.8]-나프티리딘 억제제
US6355636B1 (en) 1999-04-21 2002-03-12 American Cyanamid Company Substituted 3-cyano-[1.7],[1.5], and [1.8] naphthyridine inhibitors of tyrosine kinases
WO2000071535A1 (en) 1999-05-21 2000-11-30 Scios Inc. INDOLE-TYPE DERIVATIVES AS INHIBITORS OF p38 KINASE
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
DE60024830T2 (de) 1999-07-09 2006-06-14 Boehringer Ingelheim Pharma Verfahren zur herstellung heteroarylsubstituierter ureaverbindungen
JP4234858B2 (ja) 1999-09-21 2009-03-04 東芝テック株式会社 負極性現像剤
CN1610667A (zh) * 1999-11-27 2005-04-27 同和药品工业株式会社 新型3－硝基吡啶衍生物和含有该衍生物的药物组合物
WO2001038308A1 (en) * 1999-11-27 2001-05-31 Dong Wha Pharm. Ind. Co., Ltd Novel 5-pyrimidinecarboxamide derivatives and the pharmaceutical compositions containing said derivatives
AU1899501A (en) * 1999-11-27 2001-06-04 Dong Wha Pharmaceutical Industrial Co., Ltd. Novel 3-nitropyridine derivatives and the pharmaceutical compositions containingsaid derivatives
US6608058B2 (en) 2000-04-17 2003-08-19 Dong Wha Pharm. Ind. Co., Ltd. 6-methylnicotinamide derivatives as antiviral agents
AU2002226911A1 (en) 2000-11-20 2002-06-03 Scios Inc. Indol derivative and their use as inhibitors of p38 kinase
US7105682B2 (en) * 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
US7102009B2 (en) 2001-01-12 2006-09-05 Amgen Inc. Substituted amine derivatives and methods of use
TW593278B (en) 2001-01-23 2004-06-21 Wyeth Corp 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands
BR0207990A (pt) 2001-03-09 2004-04-27 Pfizer Prod Inc Compostos antinflamatórios de triazolopiridinas
EP1403255A4 (en) * 2001-06-12 2005-04-06 Sumitomo Pharma RHO KINASE INHIBITORS
IL160744A0 (en) 2001-09-26 2004-08-31 Pharmacia Italia Spa Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
WO2003032989A1 (en) 2001-10-18 2003-04-24 Boehringer Ingelheim Pharmaceuticals, Inc. 1,4-disubstituted benzo-fused urea compounds as cytokine inhibitors
WO2003051847A1 (en) 2001-12-19 2003-06-26 Smithkline Beecham P.L.C. (1-h-indazol-3-yl) -amide derivatives as gsk-3 inhibitors
WO2003072569A1 (en) 2002-02-25 2003-09-04 Boehringer Ingelheim Pharmaceuticals, Inc. 1,4-disubstituted benzofused cycloalkyl urea compounds useful in treating cytokine mediated diseases
FR2836915B1 (fr) 2002-03-11 2008-01-11 Aventis Pharma Sa Derives d'aminoindazoles, procede de preparation et intermediaires de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
FR2836914B1 (fr) 2002-03-11 2008-03-14 Aventis Pharma Sa Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
WO2003087072A1 (fr) 2002-03-29 2003-10-23 Mochida Pharmaceutical Co., Ltd. Agent therapeutique destine a des troubles endotheliaux
RU2354648C2 (ru) 2002-07-19 2009-05-10 Мемори Фармасьютиклз Корпорейшн Соединения 6-амино-1н-индазола и 4-аминобензофурана в качестве ингибиторов фосфодиэстеразы 4
NZ539193A (en) 2002-09-05 2008-04-30 Aventis Pharma Sa Novel aminoindazole derivatives as medicines and pharmaceutical compositions containing same
KR20050071598A (ko) 2002-10-24 2005-07-07 메르크 파텐트 게엠베하 라프-키나아제 억제제로서의 메틸렌 우레아 유도체
ES2273047T3 (es) 2002-10-28 2007-05-01 Bayer Healthcare Ag Fenilaminopirimidinas sustituidas con heteroariloxi como inhibidores de rho-cinasa.
US7196082B2 (en) 2002-11-08 2007-03-27 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
WO2004052280A2 (en) 2002-12-10 2004-06-24 Imclone Systems Incorporated Anti-angiogenic compounds and their use in cancer treatment
JP4617299B2 (ja) * 2003-03-03 2011-01-19 アレイ バイオファーマ、インコーポレイテッド ｐ３８阻害剤及びその使用法
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
GB0320244D0 (en) 2003-05-06 2003-10-01 Aventis Pharma Inc Pyrazoles as inhibitors of tumour necrosis factor
US7129252B2 (en) 2003-06-16 2006-10-31 Guoqing P Chen Six membered amino-amide derivatives an angiogenisis inhibitors
SE0301906D0 (sv) 2003-06-26 2003-06-26 Astrazeneca Ab New compounds
WO2005004818A2 (en) 2003-07-09 2005-01-20 Imclone Systems Incorporated Heterocyclic compounds and their use as anticancer agents
US7749999B2 (en) 2003-09-11 2010-07-06 Itherx Pharmaceuticals, Inc. Alpha-ketoamides and derivatives thereof
CA2547837A1 (en) 2003-12-18 2005-07-14 Boehringer Ingelheim Pharmaceuticals, Inc. Polymorph of birb 796, a p38map kinase inhibitor
MXPA06007198A (es) 2003-12-22 2006-09-04 Lilly Co Eli Antagonistas de receptor opioide.
TW200716561A (en) * 2005-05-11 2007-05-01 Array Biopharma Inc P38 inhibitors and methods of use thereof
MY151835A (en) 2006-01-31 2014-07-14 Array Biopharma Inc Kinase inhibitors and methods of use thereof

Also Published As

Publication number Publication date
KR101236608B1 (ko) 2013-02-22
IL215917A0 (en) 2011-12-29
CN101759645B (zh) 2014-06-25
DK1606283T3 (da) 2009-02-09
PL400577A1 (pl) 2013-02-18
HK1146664A1 (zh) 2011-06-30
JP2009102395A (ja) 2009-05-14
EP1997810A3 (en) 2009-12-02
US7799782B2 (en) 2010-09-21
EP1997811B1 (en) 2015-04-08
PT1606283E (pt) 2008-12-29
EP2039685A3 (en) 2009-12-02
ES2534859T3 (es) 2015-04-29
JP5424657B2 (ja) 2014-02-26
IL170527A (en) 2011-11-30
NZ542616A (en) 2009-02-28
BRPI0419305B1 (pt) 2019-10-22
NZ582796A (en) 2011-05-27
CN1784396A (zh) 2006-06-07
TWI346663B (en) 2011-08-11
PT1997811E (pt) 2015-07-29
KR20110091532A (ko) 2011-08-11
BRPI0407993B8 (pt) 2021-05-25
TW200510416A (en) 2005-03-16
IS8810A (is) 2009-03-16
CY1115441T1 (el) 2017-01-04
IL196847A0 (en) 2011-07-31
US20040176325A1 (en) 2004-09-09
US7135575B2 (en) 2006-11-14
DK1997809T3 (da) 2014-07-21
SI1606283T1 (sl) 2009-04-30
AR069413A2 (es) 2010-01-20
US8518983B2 (en) 2013-08-27
US20090136596A1 (en) 2009-05-28
DK1997810T3 (da) 2013-10-21
JP5687259B2 (ja) 2015-03-18
TW200936590A (en) 2009-09-01
EP1997810B1 (en) 2013-07-31
SI1997810T1 (sl) 2013-12-31
CY1114554T1 (el) 2016-10-05
UA103873C2 (ru) 2013-12-10
CY1116207T1 (el) 2017-02-08
DE602004016970D1 (de) 2008-11-20
DOP2009000155A (es) 2010-09-15
CN101759645A (zh) 2010-06-30
ATE410421T1 (de) 2008-10-15
BRPI0407993B1 (pt) 2018-05-22
EP2039685A2 (en) 2009-03-25
EP2039685B1 (en) 2012-12-26
CL2009000234A1 (es) 2009-04-24
NZ572694A (en) 2010-04-30
DK2039685T3 (da) 2013-03-25
CY1108661T1 (el) 2014-04-09
CL2004000416A1 (es) 2005-01-14
SI1997811T1 (sl) 2015-07-31
PT1997809E (pt) 2014-08-26
SI1997809T1 (sl) 2014-09-30
US8017641B2 (en) 2011-09-13
KR20090021231A (ko) 2009-02-27
EP1997810A2 (en) 2008-12-03
TWI343386B (en) 2011-06-11
AR043451A1 (es) 2005-07-27
US20090149459A1 (en) 2009-06-11
EG27049A (en) 2015-04-28
BRPI0407993A (pt) 2006-03-07
CO5670351A2 (es) 2006-08-31
ES2433096T3 (es) 2013-12-09
BRPI0419305B8 (pt) 2021-05-25
US20040180896A1 (en) 2004-09-16
EP1997809B1 (en) 2014-05-14
EP1997811A3 (en) 2009-09-09
ZA200507874B (en) 2007-03-28
AU2009225343A1 (en) 2009-11-05
SI2039685T1 (sl) 2013-04-30
EP1997811A2 (en) 2008-12-03
EP1997809A2 (en) 2008-12-03
PA8596901A1 (es) 2004-11-26
UA86196C2 (uk) 2009-04-10
ES2484866T3 (es) 2014-08-12
JP2012251003A (ja) 2012-12-20
EP1997809A3 (en) 2009-09-09
US20090143422A1 (en) 2009-06-04
IS2959B (is) 2017-02-15
ES2315641T3 (es) 2009-04-01
NO20085373L (no) 2005-11-29
AU2009225343B2 (en) 2012-08-23
CN100579976C (zh) 2010-01-13
PT1997810E (pt) 2013-11-07
PL219742B1 (pl) 2015-07-31
HK1084673A1 (en) 2006-08-04
KR20120037022A (ko) 2012-04-18

Similar Documents

Publication Publication Date Title
DK1997811T3 (da) Indazol-, benzoxazol- og pyrozolopyridinderivater som P38-kinasehæmmere
US7521447B2 (en) P38 inhibitors and methods of use thereof
AU2012247083B2 (en) P38 inhibitors and methods of use thereof